Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DexTech Medical ABXSAT:DEX 19 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, DexTech Medical AB ranks worse than 118905.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. DexTech Medical AB's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. DexTech Medical AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr0.57 Mil.
DexTech Medical AB (XSAT:DEX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
DexTech Medical AB Receivables Turnover Related Terms
DexTech Medical AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for DexTech Medical AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:DEX vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, DexTech Medical AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexTech Medical AB (XSAT:DEX) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DexTech Medical AB and its competitors. According to the industry distribution chart, DexTech Medical AB ranks #999999 out of 841 companies in the Biotechnology industry.
Is DexTech Medical AB's Receivables Turnover too high?
DexTech Medical AB's current Receivables Turnover is 0.00. Based on the distribution chart, DexTech Medical AB ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DexTech Medical AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #999999 out of 841 companies for Receivables Turnover. This places DexTech Medical AB in the lower half of its industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DexTech Medical AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. DexTech Medical AB's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
19GF Score
Get the complete analysis for XSAT:DEX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DEX has been successfully added to your 
